Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.55 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.46 |
| ▸ | GRM5 | P41594 | 7/20 | 0.39 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20191104 | 0.87 | CYP1A2 (0.52) | CYP1A2SCN5AGRM5ALKBH1DYRK1A | |
| SCHEMBL23572551 | 0.84 | CYP1A2 (0.52) | CYP1A2SCN5AGRM5 | |
| SCHEMBL20190955 | 0.83 | SCN5A (0.56) | CYP1A2SCN5AGRM5 | |
| SCHEMBL20209013 | 0.82 | CYP1A2 (0.67) | CYP1A2SCN5AGRM5DYRK1A | |
| SCHEMBL20191067 | 0.81 | CYP1A2 (0.50) | CYP1A2GRM5DYRK1A | |
| SCHEMBL20188664 | 0.80 | CYP1A2 (0.73) | CYP1A2SCN5AALKBH1DYRK1A | |
| SCHEMBL20208519 | 0.76 | SCN5A (0.71) | CYP1A2SCN5A | |
| SCHEMBL20209012 | 0.72 | CYP1A2 (0.74) | CYP1A2SCN5AALKBH1DYRK1A | |
| SCHEMBL26460949 | 0.72 | CYP1A2 (0.52) | CYP1A2SCN5AGRM5DYRK1A | |
| SCHEMBL23572407 | 0.72 | SCN5A (0.64) | CYP1A2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885SCN5A 8/4885GRM5 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.